Global Artificial Intelligence (AI) in Drug Discovery Market to Reach $12 Billion by 2030
The global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$12 Billion by 2030, growing at a CAGR of 25.3% over the analysis period 2022-2030. Oncology, one of the segments analyzed in the report, is projected to record 21.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Neurodegenerative Diseases segment is readjusted to a revised 22.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $594.2 Million, While China is Forecast to Grow at 24.5% CAGR
The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$594.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 24.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 21.4% and 20.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.Select Competitors (Total 293 Featured) -
- Atomwise, Inc.
- Benevolentai
- Berg LLC
- Bioage
- Cloud Pharmaceuticals, Inc.
- Cyclica
- Deep Genomics
- Envisagenics
- Exscientia
- Google (A Subsidiary of Alphabet Inc.)
- IBM Corporation
- Insilico Medicine
- Microsoft Corporation
- Numedii, Inc.
- Numerate
- NVIDIA Corporation
- Owkin, Inc.
- Twoxar, Incorporated
- Verge Genomics
- Xtalpi, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Artificial Intelligence (AI) in Drug Discovery - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Drug Optimization & Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Drug Optimization & Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World 8-Year Perspective for Preclinical Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 20: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 21: World Artificial Intelligence (AI) in Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
UNITED STATES
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 23: USA 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 25: USA 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 29: Canada 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
JAPAN
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 31: Japan 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Japan 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
CHINA
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 35: China 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 37: China 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
EUROPE
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 39: Europe 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- Table 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 41: Europe 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 43: Europe 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
FRANCE
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: France 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 47: France 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
GERMANY
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 49: Germany 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Germany 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
ITALY
- Table 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 53: Italy 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 55: Italy 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
UNITED KINGDOM
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: UK 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 59: UK 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
REST OF EUROPE
- Table 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 61: Rest of Europe 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Rest of Europe 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
ASIA-PACIFIC
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 65: Asia-Pacific 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 67: Asia-Pacific 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
REST OF WORLD
- Table 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Rest of World 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2023 & 2030
- Table 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 71: Rest of World 8-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atomwise, Inc.
- Benevolentai
- Berg LLC
- Bioage
- Cloud Pharmaceuticals, Inc.
- Cyclica
- Deep Genomics
- Envisagenics
- Exscientia
- Google (A Subsidiary of Alphabet Inc.)
- IBM Corporation
- Insilico Medicine
- Microsoft Corporation
- Numedii, Inc.
- Numerate
- NVIDIA Corporation
- Owkin, Inc.
- Twoxar, Incorporated
- Verge Genomics
- Xtalpi, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 219 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2 Billion |
Forecasted Market Value ( USD | $ 12 Billion |
Compound Annual Growth Rate | 25.1% |
Regions Covered | Global |